The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform
Suresh P. Vyas - One of the best experts on this subject based on the ideXlab platform.
-
Patents on non-viral mediated gene delivery.
Recent patents on DNA & gene sequences, 2008Co-Authors: Amit K. Goyal, Kapil Khatri, Suresh P. VyasAbstract:Gene therapy is a promising therapeutic modality for the Treatment of Genetic Disorders. Gene therapy has been able to correct many of the Genetic diseases at the root of their cause by systematizing Genetic information that encodes for all functions of every cell in our body. Recent studies have identified novel molecular targets for Genetic Disorders that can be used to deliver gene to the specific site. Gene therapy applications require safe and efficient method for gene transfer. Over the last decade, non-viral and viral gene therapy approaches have been tested in preclinical studies and human clinical trials. Gene delivery via conventional means by using viral vectors has several undesirable side effects such as insertion of mutational viral gene into the host genome and overwhelming immune and inflammatory responses. As compared to viral vectors, non-viral vehicles has received great attention due to their several favorable properties, including low toxicity and immunogenicty, resistance to nuclease, and their high affinity for DNA targets. Here, we describe how non-viral gene-transfer vehicles have been used and can be modified to target specific tissues for gene therapy. This review focuses on existing and emerging patents on non-viral based Genetic engineering strategies for the delivery of therapeutic molecules or several approaches for Genetic Disorder Treatment.
Amit K. Goyal - One of the best experts on this subject based on the ideXlab platform.
-
Patents on non-viral mediated gene delivery.
Recent patents on DNA & gene sequences, 2008Co-Authors: Amit K. Goyal, Kapil Khatri, Suresh P. VyasAbstract:Gene therapy is a promising therapeutic modality for the Treatment of Genetic Disorders. Gene therapy has been able to correct many of the Genetic diseases at the root of their cause by systematizing Genetic information that encodes for all functions of every cell in our body. Recent studies have identified novel molecular targets for Genetic Disorders that can be used to deliver gene to the specific site. Gene therapy applications require safe and efficient method for gene transfer. Over the last decade, non-viral and viral gene therapy approaches have been tested in preclinical studies and human clinical trials. Gene delivery via conventional means by using viral vectors has several undesirable side effects such as insertion of mutational viral gene into the host genome and overwhelming immune and inflammatory responses. As compared to viral vectors, non-viral vehicles has received great attention due to their several favorable properties, including low toxicity and immunogenicty, resistance to nuclease, and their high affinity for DNA targets. Here, we describe how non-viral gene-transfer vehicles have been used and can be modified to target specific tissues for gene therapy. This review focuses on existing and emerging patents on non-viral based Genetic engineering strategies for the delivery of therapeutic molecules or several approaches for Genetic Disorder Treatment.
Kapil Khatri - One of the best experts on this subject based on the ideXlab platform.
-
Patents on non-viral mediated gene delivery.
Recent patents on DNA & gene sequences, 2008Co-Authors: Amit K. Goyal, Kapil Khatri, Suresh P. VyasAbstract:Gene therapy is a promising therapeutic modality for the Treatment of Genetic Disorders. Gene therapy has been able to correct many of the Genetic diseases at the root of their cause by systematizing Genetic information that encodes for all functions of every cell in our body. Recent studies have identified novel molecular targets for Genetic Disorders that can be used to deliver gene to the specific site. Gene therapy applications require safe and efficient method for gene transfer. Over the last decade, non-viral and viral gene therapy approaches have been tested in preclinical studies and human clinical trials. Gene delivery via conventional means by using viral vectors has several undesirable side effects such as insertion of mutational viral gene into the host genome and overwhelming immune and inflammatory responses. As compared to viral vectors, non-viral vehicles has received great attention due to their several favorable properties, including low toxicity and immunogenicty, resistance to nuclease, and their high affinity for DNA targets. Here, we describe how non-viral gene-transfer vehicles have been used and can be modified to target specific tissues for gene therapy. This review focuses on existing and emerging patents on non-viral based Genetic engineering strategies for the delivery of therapeutic molecules or several approaches for Genetic Disorder Treatment.
O Wilkey - One of the best experts on this subject based on the ideXlab platform.
-
UK national standards for sickle cell disease in childhood: using audit to improve clinical care
Archives of Disease in Childhood, 2012Co-Authors: G Hann, M Roberts-harewood, Da Yardumian, O WilkeyAbstract:Background In the UK, Sickle cell disease (SCD) affects 1 in 2,400 live births and there is now a nationwide screening programme in place. There are currently estimated to be 12,500 individuals living with SCD in England where it is the most common and fastest growing Genetic Disorder. Treatment is aimed at reducing complications with preventative measures such as prophylactic antibiotics, immunisation, and cranial doppler ultrasound to assess stroke risk. Objectives This audit aims to compare local outcomes at the North Middlesex University Hospital with the recommended national standards for the management of sickle cell disease. This poster presents the results of 2 years of audit data (a full audit cycle) to assess whether recommendations made in 2009 have led to improvements in outcomes in 2010. Methods Information was retrieved via a retrospective database and notes audit of 249 patients on the haemoglobinopathy register at North Middlesex Hospital. Collated data was compared to national standards. Results The UK national standards for sickle cell disease, taken from 3 government documents (see references), were audited on 2 consecutive years. There are 13 national standards on the Treatment and management of pediatric sickle cell disease covering recommendations for newborn screening, penicillin and pneumococcal prophylaxis, transcranial doppler ultrasound (TCD) scanning and annual review. Out of 13 national targets, 6 were met in 2009 and 9 were met in 2010. Patient non attendance appointments led to a number of standards not being met in both years. Conclusions Improvement in meeting national targets occurred between 2009 and 2010 as a result of the audit process and subsequent recommendations such as changes to note keeping, the introduction of patient held records, family clinics, and the introduction of after school appointments for adolescents. The audit process itself highlighted issues such as patient non attendance and its impact on meeting standards. Non attendance remains a costly and troubling problem to the NHS where there has been a great impetus to look at the cost analysis of providing services. Steps are now being taken to reduce non attendance including a research project examining the correlation between social factors and non attendance.
G Hann - One of the best experts on this subject based on the ideXlab platform.
-
UK national standards for sickle cell disease in childhood: using audit to improve clinical care
Archives of Disease in Childhood, 2012Co-Authors: G Hann, M Roberts-harewood, Da Yardumian, O WilkeyAbstract:Background In the UK, Sickle cell disease (SCD) affects 1 in 2,400 live births and there is now a nationwide screening programme in place. There are currently estimated to be 12,500 individuals living with SCD in England where it is the most common and fastest growing Genetic Disorder. Treatment is aimed at reducing complications with preventative measures such as prophylactic antibiotics, immunisation, and cranial doppler ultrasound to assess stroke risk. Objectives This audit aims to compare local outcomes at the North Middlesex University Hospital with the recommended national standards for the management of sickle cell disease. This poster presents the results of 2 years of audit data (a full audit cycle) to assess whether recommendations made in 2009 have led to improvements in outcomes in 2010. Methods Information was retrieved via a retrospective database and notes audit of 249 patients on the haemoglobinopathy register at North Middlesex Hospital. Collated data was compared to national standards. Results The UK national standards for sickle cell disease, taken from 3 government documents (see references), were audited on 2 consecutive years. There are 13 national standards on the Treatment and management of pediatric sickle cell disease covering recommendations for newborn screening, penicillin and pneumococcal prophylaxis, transcranial doppler ultrasound (TCD) scanning and annual review. Out of 13 national targets, 6 were met in 2009 and 9 were met in 2010. Patient non attendance appointments led to a number of standards not being met in both years. Conclusions Improvement in meeting national targets occurred between 2009 and 2010 as a result of the audit process and subsequent recommendations such as changes to note keeping, the introduction of patient held records, family clinics, and the introduction of after school appointments for adolescents. The audit process itself highlighted issues such as patient non attendance and its impact on meeting standards. Non attendance remains a costly and troubling problem to the NHS where there has been a great impetus to look at the cost analysis of providing services. Steps are now being taken to reduce non attendance including a research project examining the correlation between social factors and non attendance.